Fundraising FoxAntios Therapeutics
Mendham, US · Founded 2018 · Delaware corporation · 21 known investors
Find your way into Antios Therapeutics
Sign up to see every warm intro you have to Antios Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antios Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.
Founders & leadership
Antios Therapeutics was founded in 2018 by Gregory Mayes.
Board
Investors · 21
How we know: Aisling Capital's portfolio page · lumiraventures.com · Not right? Tell us
How we know: Altium Capital's portfolio page · lumiraventures.com · Not right? Tell us
How we know: Avego BioScience Capital's portfolio page · lumiraventures.com · Not right? Tell us
How we know: LifeSci Venture Partners's portfolio page · lumiraventures.com · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: lumiraventures.com · Not right? Tell us
How we know: a partner's Signal profile · press coverage · Not right? Tell us
How we know: lumiraventures.com · Not right? Tell us
How we know: funding news · lumiraventures.com · Not right? Tell us
How we know: lumiraventures.com · Not right? Tell us
Also in the syndicate · 6
Reported raises · per SEC filings
Form D private placements$126.4M disclosed across 4 rounds · 2018–2021
▶$75MraisedNov 2021 · 35 investors · PharmaceuticalsRule 506(b)
- Benjamin RovinskiDirector
- Scott MorensteinDirector
- Tamra AdamsExecutive Officer
- Craig GordonDirector
- Gregory MayesExecutive Officer, Director
- Abel De La RosaDirector
- Douglas MayersExecutive Officer
- Patrick HigginsDirector
- Iyona RajkomarDirector
- Offering amount
- $86M
- Amount sold
- $75M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$32MraisedApr 2021 · 29 investors · PharmaceuticalsRule 506(b)
- Abel De La RosaDirector
- Iyona RajkomarDirector
- Douglas MayersExecutive Officer
- Benjamin RovinskiDirector
- Patrick HigginsDirector
- Tamra AdamsExecutive Officer
- Scott MorensteinDirector
- David CannerDirector
- Gregory MayesExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $32M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4.4MraisedAug 2020 · 9 investors · BiotechnologyRule 506(b)
- Idean MarvastyExecutive Officer
- Douglas MayersExecutive Officer
- Abel De La RosaExecutive Officer, Director
- Nicole VitulloDirector
- Henry Lin ChenDirector
- Benjamin RovinskiDirector
- Scott MorensteinDirector
- Offering amount
- $5M
- Amount sold
- $4.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15MraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
- Benjamin RovinskiDirector
- Abel De La RosaExecutive Officer, Director
- Nicole VitulioDirector
- Henry Lin ChenDirector
- Douglas MayersExecutive Officer
- Scott MorensteinDirector
- Idean MarvastyExecutive Officer
- Offering amount
- $25M
- Amount sold
- $15M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Antios Therapeutics.
In the news
Frequently asked questions
- What does Antios Therapeutics do?
- Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.
- Who founded Antios Therapeutics?
- Antios Therapeutics was founded by Gregory Mayes in 2018.
- Who are Antios Therapeutics's investors?
- Antios Therapeutics's investors include Aisling Capital, Altium Capital, Avego BioScience Capital, LifeSci Venture Partners, Pontifax Venture Capital, Amzak Health, Delos Capital, Domain Associates and 7 more.
- How much funding has Antios Therapeutics raised?
- Antios Therapeutics has disclosed $126.4M raised across 4 rounds.
- Where is Antios Therapeutics headquartered?
- Antios Therapeutics is headquartered in Mendham, US.